Niche Generic Focus Stockton Labs specializes in developing ANDA generic pharmaceuticals and operates a CMO liquid manufacturing facility, presenting a path to expand access to overlooked or small-market generics for healthcare systems seeking cost savings.

Targeted U.S. Launch Recent initiation of PangeaPharm’s Sdamlo amlodipine oral solution powder indicates capability to bring FDA‑approved generic liquid formulations to the U.S. market, signaling opportunities for RDAs, hospital systems, and long-term care providers.

Strategic Partnerships Owned CMO capabilities in San Diego support retail, unit-dose manufacturing, and repackaging, enabling BD discussions with distributors, contract manufacturers, and global pharma players seeking scalable, compliant generic production.

Growth Trajectory With revenue in the tens of millions and a lean employee base, Stockton Labs appears poised for scalable partnerships, co‑development deals, or white‑label opportunities that leverage cost leadership in niche generics.

Competitive Positioning By targeting overlooked generic opportunities and offering a domestic manufacturing foothold, Stockton Labs can differentiate from larger peers and appeal to buyers prioritizing faster entry, regulatory clarity, and minimized supply risk.